NO20071921L - Fremgangsmater for behandling av epileptogenese og epilepsi - Google Patents

Fremgangsmater for behandling av epileptogenese og epilepsi

Info

Publication number
NO20071921L
NO20071921L NO20071921A NO20071921A NO20071921L NO 20071921 L NO20071921 L NO 20071921L NO 20071921 A NO20071921 A NO 20071921A NO 20071921 A NO20071921 A NO 20071921A NO 20071921 L NO20071921 L NO 20071921L
Authority
NO
Norway
Prior art keywords
group
phenyl
alkyl
epilepsy
methods
Prior art date
Application number
NO20071921A
Other languages
English (en)
Inventor
Boyu Zhao
Roy E Twyman
Robert Gordon
Yong Moon Choi
Gerald P Novak
Carlos R Plata-Ssalaman
H Steve White
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20071921L publication Critical patent/NO20071921L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen er rettet mot fremgangsmåter for forebygging, behandling, reversering, inhibering eller arrestering av epilepsi og epileptogenese i et emneå administrere til emnet med behov derav en terapeutisk effektiv mengde av en sammensetning valgt fra gruppen bestående av formel (I) og formel (II), eller et farmasøytisk aksepterbart salt eller en ester derav, hvori fenyl er substituert ved X med en til fem halogenatomer valgt fra gruppen bestående av fluor, klor, brom og jod; og, Ri, R, R3, R4, Rs og Rer uavhengig valgt fra gruppen bestående av hydrogen og C-Calkyl; hvori C-Calkyl er valgfritt substituert med fenyl (hvori fenyl er valgfritt substituert med substituentene uavhengig valgt fra gruppen bestående av halogen, Ci-C4 alkyl, C-Calkoksy, amino, nitro og cyano).
NO20071921A 2004-09-16 2007-04-16 Fremgangsmater for behandling av epileptogenese og epilepsi NO20071921L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61027604P 2004-09-16 2004-09-16
US69862505P 2005-07-12 2005-07-12
US70724205P 2005-08-11 2005-08-11
PCT/US2005/032861 WO2006033947A2 (en) 2004-09-16 2005-09-15 Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
NO20071921L true NO20071921L (no) 2007-06-12

Family

ID=36087909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071921A NO20071921L (no) 2004-09-16 2007-04-16 Fremgangsmater for behandling av epileptogenese og epilepsi

Country Status (23)

Country Link
US (2) US20060194873A1 (no)
JP (1) JP2008513466A (no)
KR (1) KR20070057939A (no)
CN (1) CN101056629B (no)
AT (1) ATE464044T1 (no)
AU (1) AU2005287174B2 (no)
BR (1) BRPI0515374A (no)
CA (1) CA2580640A1 (no)
CO (1) CO6382111A2 (no)
CR (1) CR9053A (no)
DE (1) DE602005020667D1 (no)
DK (1) DK1809273T3 (no)
EA (1) EA200700642A1 (no)
ES (1) ES2342185T3 (no)
HK (1) HK1105583A1 (no)
HR (1) HRP20100304T1 (no)
IL (1) IL181910A0 (no)
MX (1) MX2007003278A (no)
NO (1) NO20071921L (no)
NZ (1) NZ553813A (no)
PT (1) PT1809273E (no)
RS (1) RS51269B (no)
WO (1) WO2006033947A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148052A0 (en) * 1999-08-10 2002-09-12 Uab Research Foundation Use of gaba antagonists for treatment of spastic disorders, convulsions, and epilepsy
KR20070085309A (ko) * 2004-10-15 2007-08-27 얀센 파마슈티카 엔.브이. 신경변성 질환 치료에 사용하는 카바메이트 화합물
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
SI2462990T1 (sl) 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
AU2007313911A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Treatment of Pervasive Developmental Disorders
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
RU2632659C2 (ru) 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
WO2014142477A1 (en) 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy and epilesy-related syndromes
KR101758543B1 (ko) * 2013-03-12 2017-07-14 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경가스에 의한 질환의 예방 또는 치료용 조성물
EP3423433A4 (en) * 2016-02-29 2019-12-25 Bio-Pharm Solutions Co., Ltd. SULFAMATE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
CN106053510A (zh) * 2016-05-16 2016-10-26 山东省分析测试中心 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
WO2000047202A1 (en) * 1999-02-09 2000-08-17 University Of Virginia Patent Foundation Felbamate derived compounds
CA2379365C (en) * 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
CA2439292A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
PT1408953E (pt) * 2001-02-27 2006-07-31 Ortho Mcneil Pharm Inc Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar

Also Published As

Publication number Publication date
CN101056629B (zh) 2012-01-11
JP2008513466A (ja) 2008-05-01
AU2005287174A1 (en) 2006-03-30
ATE464044T1 (de) 2010-04-15
CN101056629A (zh) 2007-10-17
IL181910A0 (en) 2007-07-04
WO2006033947A3 (en) 2006-06-29
ES2342185T3 (es) 2010-07-02
CR9053A (es) 2009-10-30
CA2580640A1 (en) 2006-03-30
EA200700642A1 (ru) 2007-10-26
BRPI0515374A (pt) 2008-07-22
US20060194873A1 (en) 2006-08-31
CO6382111A2 (es) 2012-02-15
DK1809273T3 (da) 2010-08-02
NZ553813A (en) 2010-09-30
WO2006033947A2 (en) 2006-03-30
RS51269B (sr) 2010-12-31
MX2007003278A (es) 2007-10-08
DE602005020667D1 (de) 2010-05-27
HK1105583A1 (en) 2008-02-22
PT1809273E (pt) 2010-05-10
AU2005287174B2 (en) 2012-01-12
HRP20100304T1 (hr) 2010-09-30
US20110152362A1 (en) 2011-06-23
KR20070057939A (ko) 2007-06-07

Similar Documents

Publication Publication Date Title
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
TW200744575A (en) Methods of treating epileptogenesis
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
RS67603A (en) Carbamate compounds for use in the treatment of pain
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
EA200700871A1 (ru) Способы нейропротекции
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
HK1063435A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application